32P Neutrophil to lymphocyte ratio (NLR) as a surrogate clinical marker for Ki-67 in breast cancer

Abstract

Ki-67 a cellular proliferation marker is used in breast cancer (BC) to guide therapy decision and predict prognosis in some clinical cases. It could signify treatment responsiveness/ resistance before, during and after neoadjuvant therapy. However, despite having potential applicability Ki-67 has still not been completely integrated as a standard point of care tool in clinical decision making or routine pathological reporting. Neutrophil to lymphocyte ratio (NLR) has emerged as a potential prognostic factor in various cancers, including breast cancer.